ANI Pharmaceuticals Inc (ANIP) 69.79 $ANIP
Looking For Action? S&P 1500 Most Volatile Stocks
Bespoke Investment Group - at Seeking Alpha - Tue Apr 21, 3:30AM CDT
For traders with a short-term time horizon who are looking for big moves over a short period, we have updated our list of the 50 S&P 1500 stocks trading above $10 that have the largest intraday high-low ranges (based on the average percent spread...
CRR: 33.68 (-0.12), NBR: 15.05 (+0.68), BCEI: 24.50 (-0.20), LL: 33.86 (+0.50), PTEN: 21.01 (+0.68), MNTA: 18.62 (+0.56), HOS: 20.11 (-0.89), KOP: 22.68 (+0.05), DO: 30.07 (-0.02), BBG: 9.80 (-0.41), SGY: 16.54 (-0.83), FTK: 15.56 (+0.10), SPN: 23.84 (+0.41), ROVI: 19.46 (+0.10), WPX: 13.40 (+0.16), AKRX: 53.70 (-1.69), MCF: 20.44 (-0.02), ZEUS: 10.79 (-0.32), LGND: 87.71 (-0.58), DEPO: 27.14 (+0.65), CCRN: 11.10 (+0.01), ESV: 24.03 (+0.13), ANIP: 69.79 (+1.24), SGNT: 25.43 (-0.29), PDCE: 55.02 (-0.03), NE: 16.18 (+0.14), UIHC: 20.78 (+0.18), TNGO: 14.04 (-0.16), SGMS: 12.48 (+0.25), GIFI: 15.33 (+0.25), TDW: 24.66 (-0.59), CENX: 13.28 (+0.17), UNT: 30.38 (+0.43), RIG: 16.85 (-0.18), SPOK: 20.73 (+0.23), GPRE: 30.59 (-0.02), SYRG: 12.37 (+0.06), GEOS: 20.76 (+0.57), CBM: 42.07 (-0.65), SM: 55.21 (+1.23), TESO: 12.48 (+0.09), ROSE: 22.02 (-0.50), RGEN: 33.37 (+0.51), VDSI: 25.11 (-0.58), SKYW: 14.22 (unch), GLF: 13.77 (-0.11), SLCA: 36.94 (+0.70), RDC: 19.42 (-0.13), EHTH: 11.44 (+0.07)
OncoMed Down on Phase Ib Lung Cancer Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 5:25PM CDT
OncoMed Pharmaceuticals Inc. (OMED) announced discouraging new data from a phase Ib study on demcizumab for first-line advanced non-small cell lung cancer.
OMED: 25.81 (-0.32), ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10), LLY: 72.30 (+0.09)
Oncolytics' Reolysin Gets One More Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 2:20PM CDT
Oncolytics' (ONCY) lead candidate Reolysin has been granted orphan drug status by the FDA for the treatment of malignant gliomas.
ONCY: 0.80 (unch), ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), AMGN: 169.10 (+0.64)
TrovaGene's (TROV) PCM Data Impresses, Shares Rally - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 2:08PM CDT
Shares of TrovaGene Inc. (TROV) surged 20.14% to close at $8.53 on Apr 17, after the company reported favorable clinical data for its Precision Cancer Monitoring (PCM) technology.
TROV: 8.58 (-0.27), ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), AMGN: 169.10 (+0.64)
Receptos Gains on Positive Phase II Data on Ozanimod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 4:28PM CDT
Receptos (RCPT) announced positive results from the maintenance period of the TOUCHSTONE study on ozanimod for ulcerative colitis.
ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), RCPT: 166.76 (-3.37), AFFX: 12.57 (-0.13)
The Medicines Co.'s Kengreal Backed for FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 4:57PM CDT
The Medicines Company's (MDCO) Kengreal is a step closer to U.S. approval with the FDA panel giving a favorable opinion for the treatment of percutaneous coronary intervention.
MDCO: 27.84 (+0.25), ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10), AVEO: 2.04 (+0.12)
Glaxo Downgraded to Strong Sell, Delete from Your Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 4:05PM CDT
On Apr 15, Zacks Investment Research downgraded GlaxoSmithKline plc (GSK) to a Zacks Rank #5 (Strong Sell); delete from your portfolio.
ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), GSK: 46.57 (-0.67), AFFX: 12.57 (-0.13)
GW Pharmaceuticals Up to Strong Buy on Strong Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 3:27PM CDT
On Apr 16, Zacks Investment Research upgraded GW Pharmaceuticals plc (GWPH) to a Zacks Rank #1 (Strong Buy); is it in your portfolio?
GWPH: 113.04 (-0.05), ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), AFFX: 12.57 (-0.13)
Actelion to Boost Progress of Specialty Immunology Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 11:00AM CDT
Actelion Ltd. (ALIOF) announced that it will step up its efforts to develop its specialty immunology pipeline and provided an outlook into the development plans.
ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10), SNY: 51.59 (+0.03)
ARCA biopharma Gains on Fast Track Status for Gencaro - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 3:00PM CDT
ARCA biopharma's (ABIO) experimental heart failure drug, Gencaro, has been granted Fast Track status in the U.S. for the prevention of atrial fibrillation.
MDT: 78.01 (+0.93), ANIP: 69.79 (+1.24), ABIO: 0.88 (+0.01), AMGN: 169.10 (+0.64)
Aeterna Zentaris to Advance Hormone Drug to Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 12:40PM CDT
Aeterna Zentaris Inc. (AEZS) will conduct a confirmatory phase III study to assess the efficacy of Macrilen for the treatment of AGHD.
BIIB: 423.57 (+1.46), ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10), AEZS: 0.60 (-0.03)
Adamas Pharma's Lead Candidate Gets Orphan Status in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 1:30PM CDT
Adamas Pharmaceuticals, Inc.'s (ADMS) lead candidate ADS-5102 received orphan drug status in the U.S. for levodopa-induced dyskinesia.
CYTK: 7.29 (-0.09), ADMS: 17.62 (-0.21), ANIP: 69.79 (+1.24), ACOR: 33.34 (-1.33)
Horizon Pharma's Actimmune Gets Fast Track Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 12:50PM CDT
Horizon Pharma plc (HZNP) announced that the FDA has granted fast track status to Actimmune for the treatment of Friedreich's ataxia.
CYTK: 7.29 (-0.09), ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10), ACOR: 33.34 (-1.33)
Novo Nordisk's Tresiba & Ryzodeg NDAs under FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 12:40PM CDT
Novo Nordisk A/S (NVO) announced that the FDA has accepted the Class II Resubmissions of its NDAs for Tresiba and Ryzodeg.
CYTK: 7.29 (-0.09), NVO: 56.37 (-0.17), ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10)
Clovis Oncology's Rucaparib Gets Breakthrough Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 07, 5:01PM CDT
Clovis Oncology, Inc.'s (CLVS) rucaparib received Breakthrough Therapy status from the FDA as monotherapy for advanced ovarian cancer.
CYTK: 7.29 (-0.09), CLVS: 85.04 (-1.36), ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10)
ANI Pharmaceuticals Presents At 14th Annual Needham Healthcare Conference
PR Newswire - Tue Apr 07, 3:30PM CDT
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will present on April 14, 2015 at Needham & Company's 14th Annual Healthcare Conference at the Westin Grand Central Hotel in New York City. Arthur Przybyl, President and CEO, will present at 8:40 AM ET on Tuesday, April 14, 2015. The presentation will be webcast live at http://wsw.com/webcast/needham71/anip. The live webcast will be archived and available through the prior link for 90 days through July 13, 2015.
ANIP: 69.79 (+1.24)
SAGE Therapeutics' Lead Candidate to Enter Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 2:56PM CDT
SAGE Therapeutics (SAGE) announced the details of a global phase III program on SAGE-547 for super-refractory status epilepticus.
CYTK: 7.29 (-0.09), LCI: 66.45 (-0.28), SAGE: 59.50 (-2.56), ANIP: 69.79 (+1.24)
The Best Small Cap Stocks To Buy Now
Todd Campbell - at Seeking Alpha - Mon Apr 06, 4:40AM CDT
PMC: 28.80 (+0.80), MATW: 50.74 (+0.08), ELLI: 57.00 (-0.45), SILC: 41.72 (+0.45), SGMO: 14.37 (-0.03), AFFX: 12.57 (-0.13), BABY: 41.64 (+1.71), HBIO: 6.06 (-0.29), EXAM: 42.52 (-0.16), IART: 59.75 (-0.26), SNCR: 51.87 (+0.02), CNMD: 49.35 (+0.36), BJRI: 50.54 (-1.00), NLNK: 53.12 (-0.07), CTRN: 24.27 (+0.16), ANAC: 66.45 (-0.22), PRSC: 49.43 (+0.42), RRGB: 80.99 (-2.02), ALOG: 87.92 (+0.38), DIOD: 28.02 (+0.12), LGND: 87.71 (-0.58), DEPO: 27.14 (+0.65), ASTE: 42.80 (+0.16), DYAX: 28.12 (+0.15), FARO: 44.64 (-0.93), ECOL: 48.69 (+0.16), PFPT: 58.45 (-0.45), MTSI: 34.46 (-0.27), IRWD: 15.07 (-0.19), ABAX: 63.25 (-0.09), ANIP: 69.79 (+1.24), FORM: 9.44 (+0.05), QLGC: 15.08 (+0.44), ADUS: 27.60 (-0.33), SNHY: 40.71 (+0.16), EBIX: 29.77 (+0.86), SWHC: 14.68 (-0.12)
Can Qiagen Continue to Grow in Molecular Diagnostics Space? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 01, 4:14PM CDT
On a year over year comparison, Qiagen (QGEN) reported deteriorating results on both its top and bottom line front.
CBM: 42.07 (-0.65), ANIP: 69.79 (+1.24), QGEN: 24.93 (-0.15), AFFX: 12.57 (-0.13)
ANI Pharmaceuticals Announces the Launch of Propafenone Tablets
PR Newswire - Tue Mar 31, 7:00AM CDT
ANI Pharmaceuticals, Inc. ("ANI"
(NASDAQ: ANIP) today announced the launch of Propafenone Hydrochloride 150mg, 225mg and 300mg oral tablets, indicated for use in the treatment of various arrhythmias. The overall US market for Propafenone Hydrochloride 150mg, 225mg and 300mg tablets was $14 million in 2014, per IMS Health.
ANIP: 69.79 (+1.24)
Looking For Action? S&P 1500 Most Volatile Stocks
Bespoke Investment Group - at Seeking Alpha - Tue Apr 21, 3:30AM CDT
For traders with a short-term time horizon who are looking for big moves over a short period, we have updated our list of the 50 S&P 1500 stocks trading above $10 that have the largest intraday high-low ranges (based on the average percent spread...
CRR: 33.68 (-0.12), NBR: 15.05 (+0.68), BCEI: 24.50 (-0.20), LL: 33.86 (+0.50), PTEN: 21.01 (+0.68), MNTA: 18.62 (+0.56), HOS: 20.11 (-0.89), KOP: 22.68 (+0.05), DO: 30.07 (-0.02), BBG: 9.80 (-0.41), SGY: 16.54 (-0.83), FTK: 15.56 (+0.10), SPN: 23.84 (+0.41), ROVI: 19.46 (+0.10), WPX: 13.40 (+0.16), AKRX: 53.70 (-1.69), MCF: 20.44 (-0.02), ZEUS: 10.79 (-0.32), LGND: 87.71 (-0.58), DEPO: 27.14 (+0.65), CCRN: 11.10 (+0.01), ESV: 24.03 (+0.13), ANIP: 69.79 (+1.24), SGNT: 25.43 (-0.29), PDCE: 55.02 (-0.03), NE: 16.18 (+0.14), UIHC: 20.78 (+0.18), TNGO: 14.04 (-0.16), SGMS: 12.48 (+0.25), GIFI: 15.33 (+0.25), TDW: 24.66 (-0.59), CENX: 13.28 (+0.17), UNT: 30.38 (+0.43), RIG: 16.85 (-0.18), SPOK: 20.73 (+0.23), GPRE: 30.59 (-0.02), SYRG: 12.37 (+0.06), GEOS: 20.76 (+0.57), CBM: 42.07 (-0.65), SM: 55.21 (+1.23), TESO: 12.48 (+0.09), ROSE: 22.02 (-0.50), RGEN: 33.37 (+0.51), VDSI: 25.11 (-0.58), SKYW: 14.22 (unch), GLF: 13.77 (-0.11), SLCA: 36.94 (+0.70), RDC: 19.42 (-0.13), EHTH: 11.44 (+0.07)
OncoMed Down on Phase Ib Lung Cancer Study Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 5:25PM CDT
OncoMed Pharmaceuticals Inc. (OMED) announced discouraging new data from a phase Ib study on demcizumab for first-line advanced non-small cell lung cancer.
OMED: 25.81 (-0.32), ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10), LLY: 72.30 (+0.09)
Oncolytics' Reolysin Gets One More Orphan Drug Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 2:20PM CDT
Oncolytics' (ONCY) lead candidate Reolysin has been granted orphan drug status by the FDA for the treatment of malignant gliomas.
ONCY: 0.80 (unch), ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), AMGN: 169.10 (+0.64)
TrovaGene's (TROV) PCM Data Impresses, Shares Rally - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 2:08PM CDT
Shares of TrovaGene Inc. (TROV) surged 20.14% to close at $8.53 on Apr 17, after the company reported favorable clinical data for its Precision Cancer Monitoring (PCM) technology.
TROV: 8.58 (-0.27), ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), AMGN: 169.10 (+0.64)
Receptos Gains on Positive Phase II Data on Ozanimod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 17, 4:28PM CDT
Receptos (RCPT) announced positive results from the maintenance period of the TOUCHSTONE study on ozanimod for ulcerative colitis.
ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), RCPT: 166.76 (-3.37), AFFX: 12.57 (-0.13)
The Medicines Co.'s Kengreal Backed for FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 4:57PM CDT
The Medicines Company's (MDCO) Kengreal is a step closer to U.S. approval with the FDA panel giving a favorable opinion for the treatment of percutaneous coronary intervention.
MDCO: 27.84 (+0.25), ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10), AVEO: 2.04 (+0.12)
Glaxo Downgraded to Strong Sell, Delete from Your Portfolio - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 4:05PM CDT
On Apr 15, Zacks Investment Research downgraded GlaxoSmithKline plc (GSK) to a Zacks Rank #5 (Strong Sell); delete from your portfolio.
ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), GSK: 46.57 (-0.67), AFFX: 12.57 (-0.13)
GW Pharmaceuticals Up to Strong Buy on Strong Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 3:27PM CDT
On Apr 16, Zacks Investment Research upgraded GW Pharmaceuticals plc (GWPH) to a Zacks Rank #1 (Strong Buy); is it in your portfolio?
GWPH: 113.04 (-0.05), ANIP: 69.79 (+1.24), AVEO: 2.04 (+0.12), AFFX: 12.57 (-0.13)
Actelion to Boost Progress of Specialty Immunology Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 16, 11:00AM CDT
Actelion Ltd. (ALIOF) announced that it will step up its efforts to develop its specialty immunology pipeline and provided an outlook into the development plans.
ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10), SNY: 51.59 (+0.03)
ARCA biopharma Gains on Fast Track Status for Gencaro - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 3:00PM CDT
ARCA biopharma's (ABIO) experimental heart failure drug, Gencaro, has been granted Fast Track status in the U.S. for the prevention of atrial fibrillation.
MDT: 78.01 (+0.93), ANIP: 69.79 (+1.24), ABIO: 0.88 (+0.01), AMGN: 169.10 (+0.64)
Aeterna Zentaris to Advance Hormone Drug to Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 14, 12:40PM CDT
Aeterna Zentaris Inc. (AEZS) will conduct a confirmatory phase III study to assess the efficacy of Macrilen for the treatment of AGHD.
BIIB: 423.57 (+1.46), ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10), AEZS: 0.60 (-0.03)
Adamas Pharma's Lead Candidate Gets Orphan Status in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 1:30PM CDT
Adamas Pharmaceuticals, Inc.'s (ADMS) lead candidate ADS-5102 received orphan drug status in the U.S. for levodopa-induced dyskinesia.
CYTK: 7.29 (-0.09), ADMS: 17.62 (-0.21), ANIP: 69.79 (+1.24), ACOR: 33.34 (-1.33)
Horizon Pharma's Actimmune Gets Fast Track Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 13, 12:50PM CDT
Horizon Pharma plc (HZNP) announced that the FDA has granted fast track status to Actimmune for the treatment of Friedreich's ataxia.
CYTK: 7.29 (-0.09), ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10), ACOR: 33.34 (-1.33)
Novo Nordisk's Tresiba & Ryzodeg NDAs under FDA Review - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 09, 12:40PM CDT
Novo Nordisk A/S (NVO) announced that the FDA has accepted the Class II Resubmissions of its NDAs for Tresiba and Ryzodeg.
CYTK: 7.29 (-0.09), NVO: 56.37 (-0.17), ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10)
Clovis Oncology's Rucaparib Gets Breakthrough Status - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 07, 5:01PM CDT
Clovis Oncology, Inc.'s (CLVS) rucaparib received Breakthrough Therapy status from the FDA as monotherapy for advanced ovarian cancer.
CYTK: 7.29 (-0.09), CLVS: 85.04 (-1.36), ANIP: 69.79 (+1.24), HZNP: 30.96 (+0.10)
ANI Pharmaceuticals Presents At 14th Annual Needham Healthcare Conference
PR Newswire - Tue Apr 07, 3:30PM CDT
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will present on April 14, 2015 at Needham & Company's 14th Annual Healthcare Conference at the Westin Grand Central Hotel in New York City. Arthur Przybyl, President and CEO, will present at 8:40 AM ET on Tuesday, April 14, 2015. The presentation will be webcast live at http://wsw.com/webcast/needham71/anip. The live webcast will be archived and available through the prior link for 90 days through July 13, 2015.
ANIP: 69.79 (+1.24)
SAGE Therapeutics' Lead Candidate to Enter Phase III Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 06, 2:56PM CDT
SAGE Therapeutics (SAGE) announced the details of a global phase III program on SAGE-547 for super-refractory status epilepticus.
CYTK: 7.29 (-0.09), LCI: 66.45 (-0.28), SAGE: 59.50 (-2.56), ANIP: 69.79 (+1.24)
The Best Small Cap Stocks To Buy Now
Todd Campbell - at Seeking Alpha - Mon Apr 06, 4:40AM CDT
PMC: 28.80 (+0.80), MATW: 50.74 (+0.08), ELLI: 57.00 (-0.45), SILC: 41.72 (+0.45), SGMO: 14.37 (-0.03), AFFX: 12.57 (-0.13), BABY: 41.64 (+1.71), HBIO: 6.06 (-0.29), EXAM: 42.52 (-0.16), IART: 59.75 (-0.26), SNCR: 51.87 (+0.02), CNMD: 49.35 (+0.36), BJRI: 50.54 (-1.00), NLNK: 53.12 (-0.07), CTRN: 24.27 (+0.16), ANAC: 66.45 (-0.22), PRSC: 49.43 (+0.42), RRGB: 80.99 (-2.02), ALOG: 87.92 (+0.38), DIOD: 28.02 (+0.12), LGND: 87.71 (-0.58), DEPO: 27.14 (+0.65), ASTE: 42.80 (+0.16), DYAX: 28.12 (+0.15), FARO: 44.64 (-0.93), ECOL: 48.69 (+0.16), PFPT: 58.45 (-0.45), MTSI: 34.46 (-0.27), IRWD: 15.07 (-0.19), ABAX: 63.25 (-0.09), ANIP: 69.79 (+1.24), FORM: 9.44 (+0.05), QLGC: 15.08 (+0.44), ADUS: 27.60 (-0.33), SNHY: 40.71 (+0.16), EBIX: 29.77 (+0.86), SWHC: 14.68 (-0.12)
Can Qiagen Continue to Grow in Molecular Diagnostics Space? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 01, 4:14PM CDT
On a year over year comparison, Qiagen (QGEN) reported deteriorating results on both its top and bottom line front.
CBM: 42.07 (-0.65), ANIP: 69.79 (+1.24), QGEN: 24.93 (-0.15), AFFX: 12.57 (-0.13)
ANI Pharmaceuticals Announces the Launch of Propafenone Tablets
PR Newswire - Tue Mar 31, 7:00AM CDT
ANI Pharmaceuticals, Inc. ("ANI"
(NASDAQ: ANIP) today announced the launch of Propafenone Hydrochloride 150mg, 225mg and 300mg oral tablets, indicated for use in the treatment of various arrhythmias. The overall US market for Propafenone Hydrochloride 150mg, 225mg and 300mg tablets was $14 million in 2014, per IMS Health. ANIP: 69.79 (+1.24)
